Yahoo Poland Wyszukiwanie w Internecie

Search results

1. pmc.ncbi.nlm.nih.gov › articles › PMC11425063Effect of Semaglutide in Individuals With Obesity or Overweight...

   pmc.ncbi.nlm.nih.gov › articles › PMC11425063

   The review by Bergmann et al. highlighted the significant weight loss achieved with semaglutide 2.4 mg, with participants achieving ≥10% and ≥15% weight loss. The study focused on clinical trials assessing weight loss and cardiometabolic risk factors.

2. pmc.ncbi.nlm.nih.gov › articles › PMC9486455Weight Loss Outcomes Associated With Semaglutide Treatment for...

   pmc.ncbi.nlm.nih.gov › articles › PMC9486455

   Weight Loss With Different Semaglutide Doses. In our study, 77 patients (44.0%) received the highest current doses of subcutaneous semaglutide (1.7 and 2.4 mg), while 98 (56.0%) received lower doses (0.25, 0.5, and 1 mg). Detailed information of the maximum dose reached by our cohort of patients is presented in eTable 2 in the Supplement.

3. pubmed.ncbi.nlm.nih.gov › 36254579Semaglutide for the treatment of overweight and obesity: A review

   pubmed.ncbi.nlm.nih.gov › 36254579

   18 paź 2022 · The Semaglutide Treatment Effect in People with obesity (STEP) clinical trial programme is evaluating once-weekly subcutaneous semaglutide 2.4 mg (a glucagon-like peptide-1 analogue) in people with overweight or obesity.

4. www.sciencedirect.com › science › articleLong-Term Efficacy and Safety of Once-Weekly Semaglutide for...

   www.sciencedirect.com › science › article

   1 lip 2024 · In conclusion, semaglutide is efficacious for sustained weight loss in patients with overweight/obesity and without diabetes. Semaglutide is a glucagon-like peptide-1 receptor agonist that was previously used for the treatment of hyperglycemia in patients with type 2 diabetes.

5. www.ajconline.org › article › S0002-9149(24)00319-9Long-Term Efficacy and Safety of Once-Weekly Semaglutide for...

   www.ajconline.org › article › S0002-9149(24)00319-9

   1 lip 2024 · In conclusion, semaglutide is efficacious for sustained weight loss in patients with overweight/obesity and without diabetes. Semaglutide is a glucagon-like peptide-1 receptor agonist that was previously used for the treatment of hyperglycemia in patients with type 2 diabetes.

6. www.nejm.org › doi › fullOnce-Weekly Semaglutide in Adults with Overweight or Obesity

   www.nejm.org › doi › full

   10 lut 2021 · Weight loss of 10 to 15% (or more) is recommended in people with many complications of overweight and obesity (e.g., prediabetes, hypertension, and obstructive sleep apnea). 1,20,21,27 In the...

7. www.thelancet.com › journals › lancetOral semaglutide 50 mg taken once per day in adults with...

   www.thelancet.com › journals › lancet

   26 sie 2023 · We assessed the efficacy and safety of the oral glucagon-like peptide-1 analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of overweight or obesity in adults without type 2 diabetes.